Literature DB >> 22373952

Different mutation profiles associated to P53 accumulation in colorectal cancer.

Ignacio López1, Ligia P Oliveira, Paula Tucci, Fernando Alvarez-Valín, Renata A Coudry, Mónica Marín.   

Abstract

The tumor suppressor TP53 gene is one of the most frequently mutated in different types of human cancer. Particularly in colorectal cancer (CRC), it is believed that TP53 mutations play a role in the adenoma-carcinoma transition of tumors during pathological process. In order to analyze TP53 expressed alleles in CRC, we examined TP53 mRNA in tumor samples from 101 patients with sporadic CRC. Samples were divided in two groups defined according to whether they exhibit positive or negative P53 protein expression as detected by immunohistochemistry (IHC). The presence of TP53 mutation was a common event in tumors with an overall frequency of 54.5%. By direct sequencing, we report 42 different TP53 sequence changes in 55 CRC patients, being two of them validated polymorphisms. TP53 mutations were more frequent in positive than in negative P53 detection group (p<0.0001), being the precise figures 79.6% and 30.8%, respectively. In addition, the mutation profiles were also different between the two groups of samples; while most of the mutations detected in P53 positive group were missense (38 out of 39), changes in P53 negative detection group include 7 insertions/deletions, 6 missense, 2 nonsense and 1 silent mutation. As previously observed, most mutations were concentrated in regions encoding P53 DNA binding domain (DBD). Codons 175, 248 and 273 together account for 36.7% of point mutations, in agreement with previous observations provided that these codons are considered mutation hotspots. Interestingly, we detected two new deletions and two new insertions. In addition, in three samples we detected two deletions and one insertion that could be explained as putative splicing variants or splicing errors.
Copyright © 2012 Elsevier B.V. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22373952     DOI: 10.1016/j.gene.2012.02.011

Source DB:  PubMed          Journal:  Gene        ISSN: 0378-1119            Impact factor:   3.688


  19 in total

Review 1.  P53 mutations in colorectal cancer - molecular pathogenesis and pharmacological reactivation.

Authors:  Xiao-Lan Li; Jianbiao Zhou; Zhi-Rong Chen; Wee-Joo Chng
Journal:  World J Gastroenterol       Date:  2015-01-07       Impact factor: 5.742

2.  Elevated expression of p53 in early colon polyps in a pig model of human familial adenomatous polyposis.

Authors:  Krzysztof Flisikowski; Marek Switonski; Agata Sikorska; Tatiana Flisikowska; Monika Stachowiak; Alexander Kind; Angelika Schnieke
Journal:  J Appl Genet       Date:  2018-08-25       Impact factor: 3.240

Review 3.  The functional relevance of somatic synonymous mutations in melanoma and other cancers.

Authors:  Valer Gotea; Jared J Gartner; Nouar Qutob; Laura Elnitski; Yardena Samuels
Journal:  Pigment Cell Melanoma Res       Date:  2015-11       Impact factor: 4.693

4.  Associations between cigarette smoking, hormone therapy, and folate intake with incident colorectal cancer by TP53 protein expression level in a population-based cohort of older women.

Authors:  Lori S Tillmans; Robert A Vierkant; Alice H Wang; N Jewel Samadder; Charles F Lynch; Kristin E Anderson; Amy J French; Robert W Haile; Lisa J Harnack; John D Potter; Susan L Slager; Thomas C Smyrk; Stephen N Thibodeau; James R Cerhan; Paul J Limburg
Journal:  Cancer Epidemiol Biomarkers Prev       Date:  2013-12-16       Impact factor: 4.254

5.  Correlation and prognostic significance of PD-L1 and P53 expression in resected primary pulmonary lymphoepithelioma-like carcinoma.

Authors:  Xiang-Yang Yu; Xue-Wen Zhang; Fang Wang; Yong-Bin Lin; Wei-Dong Wang; Yong-Qiang Chen; Lan-Jun Zhang; Ling Cai
Journal:  J Thorac Dis       Date:  2018-03       Impact factor: 2.895

6.  Sequential Administration of XPO1 and ATR Inhibitors Enhances Therapeutic Response in TP53-mutated Colorectal Cancer.

Authors:  Akira Inoue; Frederick S Robinson; Rosalba Minelli; Hideo Tomihara; Bahar Salimian Rizi; Johnathon L Rose; Takahiro Kodama; Sanjana Srinivasan; Angela L Harris; Andy M Zuniga; Robert A Mullinax; Xiaoyan Ma; Sahil Seth; Joseph R Daniele; Michael D Peoples; Sara Loponte; Kadir C Akdemir; Tin Oo Khor; Ningping Feng; Jason Roszik; Mary M Sobieski; David Brunell; Clifford Stephan; Virginia Giuliani; Angela K Deem; Takashi Shingu; Yonathan Lissanu Deribe; David G Menter; Timothy P Heffernan; Andrea Viale; Christopher A Bristow; Scott Kopetz; Giulio F Draetta; Giannicola Genovese; Alessandro Carugo
Journal:  Gastroenterology       Date:  2021-03-19       Impact factor: 33.883

7.  Biomarkers in precision therapy in colorectal cancer.

Authors:  Marlies S Reimers; Eliane C M Zeestraten; Peter J K Kuppen; Gerrit Jan Liefers; Cornelis J H van de Velde
Journal:  Gastroenterol Rep (Oxf)       Date:  2013-08-23

8.  Defective autophagosome formation in p53-null colorectal cancer reinforces crocin-induced apoptosis.

Authors:  Amr Amin; Khuloud Bajbouj; Adrian Koch; Muktheshwar Gandesiri; Regine Schneider-Stock
Journal:  Int J Mol Sci       Date:  2015-01-09       Impact factor: 5.923

Review 9.  Dysregulation of miRNAs in bladder cancer: altered expression with aberrant biogenesis procedure.

Authors:  Fan Dong; Tianyuan Xu; Yifan Shen; Shan Zhong; Shanwen Chen; Qiang Ding; Zhoujun Shen
Journal:  Oncotarget       Date:  2017-04-18

10.  Comparative study and meta-analysis of meta-analysis studies for the correlation of genomic markers with early cancer detection.

Authors:  Zoi Lanara; Efstathia Giannopoulou; Marta Fullen; Evangelos Kostantinopoulos; Jean-Christophe Nebel; Haralabos P Kalofonos; George P Patrinos; Cristiana Pavlidis
Journal:  Hum Genomics       Date:  2013-06-05       Impact factor: 4.639

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.